Fabry Disease Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the fabry disease treatment market size is expected to grow from USD 2.63 billion in 2025 to USD 2.83 billion in 2026 and is forecast to reach USD 4.09 billion by 2031 at 7.63% CAGR over 2026-2031.

This report is Segmented by Treatment (Enzyme Replacement Therapy, and More), Route of Administration (Intravenous, Oral, and Subcutaneous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Fabry Disease Treatment Market Trends and Insights

Growing Prevalence of Fabry Disease

Re-evaluation of screening programs indicates Fabry disease affects nearly 1 in 10,000 individuals, a four-fold increase on earlier estimates. Late-onset forms account for most symptomatic cases and often escape detection until organ damage progresses, which creates a significant latent pool of untreated adults. Broader renal and cardiology screening plus newborn testing in several countries funnels higher numbers of presymptomatic carriers into specialty clinics. This expanding patient funnel underpins sustained demand in the Fabry disease treatment market.

Advances in Gene and mRNA Therapies

Multiple AAV-based vectors now show persistent a-galactosidase A expression for at least two years, minimizing immunogenicity and infusion burden. FDA agreement on an accelerated approval path for Sangamo's ST-920 underscores rising regulatory confidence in biomarker-driven endpoints. uniQure's AMT-191 and Exegenesis Bio's EXG110 hold orphan designations and early safety data support single-dose curative potential. Each milestone heightens investor interest and propels the Fabry disease treatment market toward transformative modalities.

High Treatment Costs and Payer Budget Constraints

Elfabrio's annual price surpasses USD 430,000, placing Fabry therapy among the costliest prescriptions worldwide. Insurers often restrict reimbursement until organ pathology is documented, delaying initiation and potentially worsening prognosis. Variable public financing leaves emerging-market patients exposed to catastrophic out-of-pocket fees, muting penetration rates in the Fabry disease treatment market despite rising clinical need.

Other drivers and restraints analyzed in the detailed report include:

1. Favorable Orphan-Drug Incentives and Fast-Track Designations
2. Increasing Global Healthcare Expenditure on Rare Diseases
3. Limited Diagnostic Infrastructure in Emerging Markets

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Enzyme replacement therapy generated 67.85% of Fabry disease treatment market revenue in 2025 and continues to anchor clinical practice due to decades of safety data. However, gene therapy is forecast to post a 9.18% CAGR, reflecting patient demand for single-dose, potentially curative solutions. Oral chaperone migalastat addresses amenable mutations, and substrate reduction agent venglustat is in Phase III for neuropathic pain management. The diversified pipeline signals that the Fabry disease treatment market will transition toward modality pluralism rather than a single therapeutic hegemon.

Gene therapy sponsors improve vector tropism and dosing efficiency, reducing manufacturing cost and immunogenic risk. Pegunigalsidase alfa's monthly infusion option demonstrates legacy ERT innovation while biosimilar entries loom as patents expire. Collectively, these shifts promise a more competitive and patient-centric Fabry disease treatment market over the next decade.

Complete Report Scope:

• By Treatment
  • Enzyme Replacement Therapy
  • Oral Chaperone Therapy
  • Gene Therapy
  • Substrate Reduction Therapy
  • Other Treatments
• By Route of Administration
  • Intravenous
  • Oral
  • Subcutaneous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
      • GCC
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America led with 42.85% Fabry disease treatment market revenue in 2025 underpinned by broad newborn screening, specialist centers, and comprehensive reimbursement. The FDA routinely applies priority and breakthrough designations, enabling swift adoption of novel modalities. Despite payer scrutiny, commercial plans typically cover enzyme replacement and migalastat, while multiple gene therapy trials recruit aggressively across the United States and Canada.

Europe ranks second, benefiting from cross-border regulatory harmonization via the EMA and robust academic registries tracking long-term outcomes. National health technology assessments can delay uptake but ultimately assure broad coverage. Recent Scottish approval for pegunigalsidase alfa highlights continued regional expansion of the Fabry disease treatment market. EU research consortia and patient groups provide an integrated ecosystem that supports evidence generation and guideline refinement.

Asia-Pacific is the fastest growing zone at an 8.28% CAGR. Japan's conditional early-access framework and South Korea's national insurance adoption of ERT illustrate mature system capacity. China's rare-disease catalog, expanded reimbursement, and domestic biotech investment collectively accelerate penetration. Rising clinical trial activity and infrastructure upgrades in India and Southeast Asia suggest further upside for the Fabry disease treatment market over the horizon.

1. Sanofi
2. Takeda Pharmaceuticals
3. Amicus Therapeutics
4. Chiesi Farmaceutici
5. Protalix BioTherapeutics
6. JCR Pharmaceuticals
7. ISU ABXIS
8. Freeline Therapeutics
9. Yuhan Corporation
10. M6P Therapeutics
11. AVROBIO
12. Sangamo Therapeutics
13. 4D Molecular Therapeutics
14. Idorsia
15. BioMarin Pharmaceutical
16. Orchard Therapeutics
17. Moderna Tx
18. Ultragenyx
19. Rocket Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support